MedTrace Logo

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 508

Last updated 2026-04-30

No results posted yet for this study

Summary

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Conditions

  • Relapsed Refractory Multiple Myeloma

Interventions

BIOLOGICAL

AZD0120

CAR-T Cells

DRUG

Daratumumab

Daratumumab

DRUG

Carfilzomib

Carfilzomib

DRUG

Dexamethasone

Dexamethasone

DRUG

Bortezomib

Bortezomib

DRUG

Pomalidomide

Pomalidomides

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-23
Primary Completion
2028-06-14
Completion
2030-08-12
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • France
  • Germany
  • Italy
  • Japan
  • Norway
  • Poland
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07391657 on ClinicalTrials.gov